Navigation Links
Hormone therapy offers potential protective effect against colon cancer in older women
Date:4/22/2009

DENVER In a large study, a national team of researchers led by Mayo Clinic scientists observed that self-reported use of hormone therapy was associated with a significantly lower colorectal cancer risk. However, the mechanisms for the apparent protective association are still unclear.

The study, being presented at the AACR 100th Annual Meeting 2009, was designed to look at possible links between estrogen exposure and colon cancer molecular subtypes, to determine how these hormones might function as anti-cancer agents.

"In our large, prospective study, use of hormone therapy seemed to be beneficial with respect to reducing colorectal cancer risk women who did use these drugs had a 28 percent lower incidence rate than women who did not use these drugs," says the study's lead author, David Limsui, M.D., a fellow in the Department of Gastroenterology at Mayo Clinic's campus in Rochester, Minn. "But we still don't know how estrogen compounds work in cancer prevention, which is intriguing."

Women who reported using other hormone preparations, such as oral contraceptives, did not appear to derive any colorectal cancer prevention benefits. "Based on our findings, we need to continue exploring the cancer pathways that might be affected by these hormones," Dr. Limsui says.

He adds that other studies have also found that hormone therapy protects postmenopausal women against colon cancer. The largest randomized clinical trial was the 16,000-participant Women's Health Initiative, which concluded in 2004 that combination hormone therapy (estrogen and progestin) reduced a woman's risk of colorectal cancer by about 40 percent, he says. "But few studies have delved deeper to see how these hormones work at the molecular level," Dr. Limsui says.

This investigation is part of the Iowa Women's Health Study, which enrolled 41,836 women from Iowa, aged 55-69, in 1986. After exclusions, the study group consisted of 37,285 women. In the current study, the investigators examined tumor tissue from 553 colorectal cancer patients, specifically looking for associations between self-reported hormone use and a specific DNA methylation pattern, called the CpG island methylator phenotype, or BRAF gene mutations. No associations were detected between hormone use and these molecular markers. Of note, the investigative team previously reported that certain environmental exposures, such as cigarette smoking, might increase colorectal cancer risk through DNA methylation pathways.


'/>"/>

Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Female hormone cycle affects knee joints
2. IROs Help Determine Medical Necessity of Growth Hormone Therapy
3. A potential new target for treatment of hormone refractory prostate cancer
4. Male Hormone Treatment Provider Announces Family Doctor Alert
5. Autism linked with stress hormone levels
6. Organic Left Standing as the Gold Standard for Consumers Looking to Avoid Food Produced With Synthetic Growth Hormones
7. Hormone Reduces Mortality in Heart Patients With High BP
8. Diplomat Specialty Pharmacy Expands National Growth Hormone Patient Care Program - Hires Denise Piro, RN, BSN
9. Hormone Might Help Restore Female Fertility
10. March 2009 Mayo Clinic Womens HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women
11. Male Hormone Replacement Company Renewman.com Critical of MLB for Testosterone Abuse Publicity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has ... chances of acceptance to a residency in a United States hospital. Being accepted ... the U.S. , According to data released by the ECFMG®, every year, 50 ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/21/2017)... ONTARIO, CANADA (PRWEB) , ... July 21, 2017 ... ... give insight into why concussion rates are on the rise, say researchers presenting ... Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology: